Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes

Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRN...

Full description

Saved in:
Bibliographic Details
Published inOncotarget Vol. 5; no. 20; pp. 9864 - 9876
Main Authors Su, Xiaoping, Malouf, Gabriel G., Chen, Yunxin, Zhang, Jianping, Yao, Hui, Valero, Vicente, Weinstein, John N., Spano, Jean-Philippe, Meric-Bernstam, Funda, Khayat, David, Esteva, Francisco J.
Format Journal Article
LanguageEnglish
Published United States Impact Journals LLC 30.10.2014
Subjects
Online AccessGet full text
ISSN1949-2553
1949-2553
DOI10.18632/oncotarget.2454

Cover

Abstract Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis- and trans-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome.
AbstractList Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis - and trans -acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome.
Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis- and trans-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome.
Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis- and trans-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome.Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role of lncRNA expression in human breast cancer biology, prognosis and molecular classification remains unknown. Herein, we established the lncRNA profile of 658 infiltrating ductal carcinomas of the breast from The Cancer Genome Atlas project. We found lncRNA expression to correlate with the gene expression and chromatin landscape of human mammary epithelial cells (non-transformed) and the breast cancer cell line MCF-7. Unsupervised consensus clustering of lncRNA revealed four subgroups that displayed different prognoses. Gene set enrichment analysis for cis- and trans-acting lncRNAs showed enrichment for breast cancer signatures driven by master regulators of breast carcinogenesis. Interestingly, the lncRNA HOTAIR was significantly overexpressed in the HER2-enriched subgroup, while the lncRNA HOTAIRM1 was significantly overexpressed in the basal-like subgroup. Estrogen receptor (ESR1) expression was associated with distinct lncRNA networks in lncRNA clusters III and IV. Importantly, almost two thirds of the lncRNAs were marked by enhancer chromatin modifications (i.e., H3K27ac), suggesting that expressed lncRNA in breast cancer drives carcinogenesis through increased activity of neighboring genes. In summary, our study depicts the first lncRNA subtype classification in breast cancer and provides the framework for future studies to assess the interplay between lncRNAs and the breast cancer epigenome.
Author Esteva, Francisco J.
Malouf, Gabriel G.
Spano, Jean-Philippe
Khayat, David
Meric-Bernstam, Funda
Zhang, Jianping
Weinstein, John N.
Chen, Yunxin
Yao, Hui
Valero, Vicente
Su, Xiaoping
AuthorAffiliation 3 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
4 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2 Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France
1 Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
5 Breast Medical Oncology Program, New York University Cancer Institute, New York, NY, USA
AuthorAffiliation_xml – name: 2 Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France
– name: 1 Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– name: 4 Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– name: 5 Breast Medical Oncology Program, New York University Cancer Institute, New York, NY, USA
– name: 3 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Author_xml – sequence: 1
  givenname: Xiaoping
  surname: Su
  fullname: Su, Xiaoping
  organization: Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– sequence: 2
  givenname: Gabriel G.
  surname: Malouf
  fullname: Malouf, Gabriel G.
  organization: Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France
– sequence: 3
  givenname: Yunxin
  surname: Chen
  fullname: Chen, Yunxin
  organization: Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– sequence: 4
  givenname: Jianping
  surname: Zhang
  fullname: Zhang, Jianping
  organization: Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– sequence: 5
  givenname: Hui
  surname: Yao
  fullname: Yao, Hui
  organization: Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– sequence: 6
  givenname: Vicente
  surname: Valero
  fullname: Valero, Vicente
  organization: Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– sequence: 7
  givenname: John N.
  surname: Weinstein
  fullname: Weinstein, John N.
  organization: Departments of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– sequence: 8
  givenname: Jean-Philippe
  surname: Spano
  fullname: Spano, Jean-Philippe
  organization: Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France
– sequence: 9
  givenname: Funda
  surname: Meric-Bernstam
  fullname: Meric-Bernstam, Funda
  organization: Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
– sequence: 10
  givenname: David
  surname: Khayat
  fullname: Khayat, David
  organization: Groupe Hospitalier Pitié-Salpêtrière, Department of Medical Oncology, University Pierre and Marie Curie (Paris VI), Institut Universitaire de Cancérologie, AP-HP, Paris, France
– sequence: 11
  givenname: Francisco J.
  surname: Esteva
  fullname: Esteva, Francisco J.
  organization: Breast Medical Oncology Program, New York University Cancer Institute, New York, NY, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25296969$$D View this record in MEDLINE/PubMed
BookMark eNp1UVtLHDEYDbJSt1vffZI8-jJ2cpudvAiyVC1IBVF8DNnMN7spmWRNMsL--8bLWlvwC3w5kHOBnK9o4oMHhI5IfUrahtHvwZuQdVxBPqVc8D00JZLLigrBJh_wATpM6XddRvB5S-UXdEAFlU05U_SwCMMmwhp8sk-Atddum2zCoccu-BUumZUJnS3w9td5wtbj9Thoj5cRdMrYaG8gYuOst0Y7nMZl3m4gfUP7vXYJDt_uGbq_-HG3uKquby5_Ls6vK8MbmisjgVAtWyZF3S0ZGNazsjXMiehEq1tBBHR10_dtT4kQXMiaSyEZ6dsGxJzN0Nmr72ZcDtAZ8DlqpzbRDjpuVdBW_fvi7VqtwpPiVEjOWTE4eTOI4XGElNVgkwHntIcwJkUayiXjjJNCPf6Y9R6y-81CaF4JJoaUIvTK2KyzDc_R1ilSq5fm1N_m1HNzRVj_J9x5fyr5A9RfoJc
CitedBy_id crossref_primary_10_1042_BCJ20170664
crossref_primary_10_1016_j_gene_2020_145063
crossref_primary_10_1371_journal_pone_0163238
crossref_primary_10_3389_fgene_2018_00471
crossref_primary_10_3892_ol_2016_4770
crossref_primary_10_1111_jog_13840
crossref_primary_10_1038_srep37821
crossref_primary_10_18632_oncotarget_24591
crossref_primary_10_1002_jcb_27770
crossref_primary_10_1007_s12253_018_00570_4
crossref_primary_10_18632_oncotarget_9880
crossref_primary_10_1002_jcla_22193
crossref_primary_10_18632_oncotarget_19727
crossref_primary_10_1111_and_13897
crossref_primary_10_3390_ijms22126374
crossref_primary_10_1007_s11033_021_06847_3
crossref_primary_10_18632_oncotarget_14313
crossref_primary_10_1038_labinvest_2015_80
crossref_primary_10_1186_s12967_018_1640_2
crossref_primary_10_1186_s13045_018_0596_2
crossref_primary_10_1158_1078_0432_CCR_15_1555
crossref_primary_10_4048_jbc_2018_21_e41
crossref_primary_10_1093_hmg_ddw177
crossref_primary_10_15252_emmm_201606198
crossref_primary_10_18632_oncotarget_6420
crossref_primary_10_1016_j_bbagen_2017_04_007
crossref_primary_10_1089_gtmb_2019_0102
crossref_primary_10_3390_ijms26010127
crossref_primary_10_1261_rna_073254_119
crossref_primary_10_18632_oncotarget_14304
crossref_primary_10_3390_cells12081159
crossref_primary_10_3390_ijms23010201
crossref_primary_10_1002_jcp_25997
crossref_primary_10_3390_sci2020024
crossref_primary_10_1007_s10549_016_3826_8
crossref_primary_10_1016_j_bbcan_2022_188747
crossref_primary_10_1049_syb2_12020
crossref_primary_10_1158_0008_5472_CAN_16_2634
crossref_primary_10_3390_cancers14092115
crossref_primary_10_1093_nar_gkw966
crossref_primary_10_1016_j_omtn_2021_08_005
crossref_primary_10_1093_gigascience_giz145
crossref_primary_10_1007_s40139_017_0122_1
crossref_primary_10_1080_14737159_2018_1538794
crossref_primary_10_3727_096504016X14618564639178
crossref_primary_10_3390_ijms23063189
crossref_primary_10_2217_epi_2015_0012
crossref_primary_10_1038_s41419_020_2416_1
crossref_primary_10_1158_0008_5472_CAN_15_3284
crossref_primary_10_1038_s41419_023_05609_2
crossref_primary_10_1186_s12967_016_1025_3
crossref_primary_10_1007_s10911_022_09511_z
crossref_primary_10_1016_j_ejmech_2017_07_075
crossref_primary_10_1016_j_biopha_2018_08_105
crossref_primary_10_1007_s13237_017_0201_z
crossref_primary_10_18632_oncotarget_24403
crossref_primary_10_2147_JHC_S415318
crossref_primary_10_1002_cam4_1523
crossref_primary_10_1007_s13311_019_00799_0
crossref_primary_10_1038_s41523_019_0144_4
crossref_primary_10_18632_oncotarget_3457
crossref_primary_10_1038_s42003_022_03559_7
crossref_primary_10_18632_oncotarget_22063
crossref_primary_10_3390_ijms17091485
crossref_primary_10_18632_aging_102205
crossref_primary_10_1016_j_ymthe_2018_08_026
crossref_primary_10_1038_s41388_020_1365_6
crossref_primary_10_3390_genes12121978
crossref_primary_10_3892_mmr_2017_7606
crossref_primary_10_3390_ijms19092711
crossref_primary_10_1186_s13058_015_0557_4
crossref_primary_10_18632_oncotarget_4419
crossref_primary_10_3892_or_2017_5821
crossref_primary_10_1016_j_bbrc_2016_05_031
crossref_primary_10_1016_j_bbagrm_2019_04_005
crossref_primary_10_1038_s41598_021_86923_7
crossref_primary_10_1016_j_ijbiomac_2017_03_021
crossref_primary_10_1039_C7RA12131H
crossref_primary_10_1158_0008_5472_CAN_17_3486
crossref_primary_10_3389_fonc_2024_1458588
crossref_primary_10_3389_fonc_2021_752579
crossref_primary_10_12688_f1000research_27393_2
crossref_primary_10_1158_0008_5472_CAN_15_0506
crossref_primary_10_12688_f1000research_27393_3
crossref_primary_10_3389_fcell_2020_00368
crossref_primary_10_1186_s12943_019_1021_3
crossref_primary_10_3390_sci3020026
crossref_primary_10_3390_ijms17081357
crossref_primary_10_1007_s13277_015_4572_y
crossref_primary_10_1111_jcmm_12681
crossref_primary_10_3390_ncrna4010007
crossref_primary_10_1016_j_compbiolchem_2018_11_008
crossref_primary_10_18632_oncotarget_8192
crossref_primary_10_7717_peerj_8797
crossref_primary_10_1038_srep41960
crossref_primary_10_1038_s41598_017_17996_6
crossref_primary_10_1016_j_ygeno_2021_07_015
crossref_primary_10_1038_s41598_020_65109_7
crossref_primary_10_1111_cge_13502
crossref_primary_10_3390_pharmaceutics15082096
crossref_primary_10_1007_s13277_015_3714_6
crossref_primary_10_1038_s41598_020_71062_2
crossref_primary_10_1016_j_prp_2019_03_033
crossref_primary_10_1093_bfgp_elv049
crossref_primary_10_18632_oncotarget_13384
crossref_primary_10_7717_peerj_13641
crossref_primary_10_18632_oncotarget_7559
crossref_primary_10_3390_cancers13143530
crossref_primary_10_3390_cells8060605
crossref_primary_10_1530_ERC_17_0548
crossref_primary_10_1093_bioinformatics_btad276
crossref_primary_10_1002_jcb_27584
crossref_primary_10_1002_ijc_33539
crossref_primary_10_1126_sciadv_1600220
crossref_primary_10_1371_journal_pone_0314973
crossref_primary_10_1186_s12943_017_0580_4
crossref_primary_10_3390_cancers13215350
crossref_primary_10_18632_oncotarget_11998
crossref_primary_10_3892_ijo_2015_3292
crossref_primary_10_1002_1878_0261_12489
crossref_primary_10_18632_oncotarget_6859
crossref_primary_10_18632_oncotarget_9608
crossref_primary_10_1186_s12935_018_0674_0
crossref_primary_10_18632_oncotarget_9622
crossref_primary_10_1016_j_bone_2015_05_026
crossref_primary_10_1002_jcp_27036
crossref_primary_10_1016_j_ebiom_2016_02_028
crossref_primary_10_3389_fgene_2022_932060
crossref_primary_10_18632_oncotarget_10213
crossref_primary_10_18632_oncotarget_17409
crossref_primary_10_1039_C6MB00585C
crossref_primary_10_1007_s10142_023_01112_1
crossref_primary_10_1186_s12967_020_02320_0
crossref_primary_10_3390_ijms21197407
crossref_primary_10_1093_bib_bbv114
crossref_primary_10_3892_etm_2017_5573
crossref_primary_10_18632_oncotarget_5399
crossref_primary_10_1038_s41598_017_00823_3
crossref_primary_10_1186_s12935_021_02362_4
crossref_primary_10_1007_s44178_022_00009_6
crossref_primary_10_1007_s10753_023_01919_x
crossref_primary_10_3390_ijms19010123
crossref_primary_10_1038_s41598_020_69905_z
crossref_primary_10_3390_cancers14235980
crossref_primary_10_1002_jcb_29621
crossref_primary_10_1007_s13277_016_5426_y
crossref_primary_10_1039_C7RA12042G
crossref_primary_10_18632_oncotarget_14522
crossref_primary_10_1016_j_gene_2020_145033
crossref_primary_10_1172_jci_insight_168988
crossref_primary_10_1186_s12967_015_0556_3
crossref_primary_10_1139_bcb_2018_0039
crossref_primary_10_1186_s12885_019_6338_1
Cites_doi 10.1007/s10549-012-2314-z
10.1038/ng.131
10.1182/blood-2008-06-162164
10.1073/pnas.0408974102
10.18632/oncotarget.1769
10.1186/bcr2937
10.1214/07-AOAS101
10.1073/pnas.191367098
10.1158/0008-5472.CAN-13-1896
10.1101/gad.1800909
10.1016/j.tig.2011.06.009
10.1093/hmg/ddq362
10.1038/nsmb.2591
10.1038/cr.2010.114
10.1038/nature07672
10.1200/JCO.2008.18.1370
10.1080/07357900701784238
10.1038/nbt.1630
10.1038/nrg2521
10.1073/pnas.0506580102
10.1016/j.cell.2010.09.001
10.1016/j.gde.2011.01.020
10.1101/gr.132159.111
10.1172/JCI60534
10.1002/emmm.201100122
10.1371/journal.pcbi.1000176
10.1016/j.cell.2012.02.008
10.1073/pnas.1933744100
10.1101/gad.17446611
10.1371/journal.pgen.0020047
10.1038/nature08975
10.1038/nbt.1914
10.1038/nmeth.1179
10.1038/35021093
10.1016/j.tcb.2011.04.001
10.1038/nature07107
10.1007/s10911-012-9245-5
10.1186/gb-2010-11-10-r106
ContentType Journal Article
Copyright Copyright: © 2014 Su et al. 2014
Copyright_xml – notice: Copyright: © 2014 Su et al. 2014
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.18632/oncotarget.2454
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1949-2553
EndPage 9876
ExternalDocumentID PMC4259443
25296969
10_18632_oncotarget_2454
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: P30 CA016672
– fundername: NCI NIH HHS
  grantid: P50 CA100632
– fundername: NCATS NIH HHS
  grantid: UL1 TR000371
– fundername: NCATS NIH HHS
  grantid: UL1TR000371
GroupedDBID ---
53G
AAYXX
ADBBV
ADRAZ
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
FRJ
GX1
HYE
KQ8
M48
OK1
PGMZT
RPM
CGR
CUY
CVF
ECM
EIF
M~E
NPM
7X8
5PM
ID FETCH-LOGICAL-c462t-c9e12a983950db3ec3f33ecae715d58a8515ed06ff8f21554590495931f86e573
IEDL.DBID M48
ISSN 1949-2553
IngestDate Thu Aug 21 17:51:38 EDT 2025
Thu Jul 10 21:03:19 EDT 2025
Sat Sep 28 07:56:40 EDT 2024
Thu Apr 24 23:13:16 EDT 2025
Tue Jul 01 02:40:20 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 20
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-c9e12a983950db3ec3f33ecae715d58a8515ed06ff8f21554590495931f86e573
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.18632/oncotarget.2454
PMID 25296969
PQID 1624934341
PQPubID 23479
PageCount 13
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4259443
proquest_miscellaneous_1624934341
pubmed_primary_25296969
crossref_citationtrail_10_18632_oncotarget_2454
crossref_primary_10_18632_oncotarget_2454
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-10-30
PublicationDateYYYYMMDD 2014-10-30
PublicationDate_xml – month: 10
  year: 2014
  text: 2014-10-30
  day: 30
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Oncotarget
PublicationTitleAlternate Oncotarget
PublicationYear 2014
Publisher Impact Journals LLC
Publisher_xml – name: Impact Journals LLC
References Huang (22) 2010; 143
Hayes (34) 2003; 100
Jeffrey (9) 2001; 98
Mattick (13) 2009; 10
Gregori (15) 2012; 136
Shiekhattar (16) 2011; 21
Greenwood (30) 2011; 3
Creighton (25) 2012; 6
Knowles (24) 2012; 22
Shu (5) 2014
Lander (40) 2005; 102
Ma (11) 2012; 17
Bell (20) 2012; 148
Lee (33) 2014; 74
Akslen (8) 2000; 406
Bejerano (19) 2010; 28
Huber (38) 2010; 11
Rimm (36) 2011; 13
Wang (4) 2014
Huang (37) 2008; 5
Jaffe (27) 2008; 454
Chang (2) 2011; 21
Rinn (14) 2010; 464
Belgard (12) 2010; 19
Cassady (39) 2009; 458
Rinn (23) 2011; 25
Yang (28) 2006; 2
Tibshirani (41) 2007; 1
Aben (21) 2008; 40
Buchholz (31) 2005; 102
Carey (18) 2008; 26
Mattick (29) 2008; 4
Shiekhattar (17) 2011; 27
Liu (6) 2013; 20
Kominsky (35) 2011; 29
Spector (1) 2009; 23
Hu (10) 2009; 27
Newburger (32) 2009; 113
Zhang (26) 2010; 20
Farrar (3) 2014; 5
Polyak (7) 2011; 121
19043537 - PLoS Comput Biol. 2008 Nov;4(11):e1000176
19204204 - J Clin Oncol. 2009 Mar 10;27(8):1160-7
22350981 - J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):33-42
20979621 - Genome Biol. 2010;11(10):R106
23124417 - Breast Cancer Res Treat. 2012 Dec;136(3):875-83
22385965 - Cell. 2012 Mar 2;148(5):1015-28
16683030 - PLoS Genet. 2006 Apr;2(4):e47
19144990 - Blood. 2009 Mar 12;113(11):2526-34
21888627 - Breast Cancer Res. 2011;13(5):R85
19571179 - Genes Dev. 2009 Jul 1;23(13):1494-504
14500907 - Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
15914550 - Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20
21890647 - Genes Dev. 2011 Sep 15;25(18):1915-27
11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
21550244 - Trends Cell Biol. 2011 Jun;21(6):354-61
23728290 - Nat Struct Mol Biol. 2013 Jul;20(7):908-13
19182780 - Nature. 2009 Mar 12;458(7235):223-7
18204455 - Nat Methods. 2008 Feb;5(2):183-8
19188922 - Nat Rev Genet. 2009 Mar;10(3):155-9
22955988 - Genome Res. 2012 Sep;22(9):1775-89
20680032 - Cell Res. 2010 Oct;20(10):1109-16
18600261 - Nature. 2008 Aug 7;454(7205):766-70
18181038 - Cancer Invest. 2008 Feb;26(1):1-10
21831473 - Trends Genet. 2011 Oct;27(10):433-9
21965334 - J Clin Invest. 2011 Oct;121(10):3786-8
20436461 - Nat Biotechnol. 2010 May;28(5):495-501
20887892 - Cell. 2010 Oct 1;143(1):46-58
20393566 - Nature. 2010 Apr 15;464(7291):1071-6
24519926 - Oncotarget. 2014 Feb 15;5(3):764-74
21804560 - Nat Biotechnol. 2011 Aug;29(8):742-9
21337521 - EMBO Mol Med. 2011 Mar;3(3):167-80
21330130 - Curr Opin Genet Dev. 2011 Apr;21(2):194-8
24631686 - Biochem Biophys Res Commun. 2014 Apr 4;446(2):448-53
18438407 - Nat Genet. 2008 Jun;40(6):703-6
20798109 - Hum Mol Genet. 2010 Oct 15;19(R2):R162-8
10963602 - Nature. 2000 Aug 17;406(6797):747-52
22956860 - Biologics. 2012;6:289-97
24491801 - Cancer Res. 2014 Mar 15;74(6):1705-17
24388988 - Biochem Biophys Res Commun. 2014 Jun 6;448(3):315-22
16199517 - Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
References_xml – volume: 136
  start-page: 875
  year: 2012
  ident: 15
  article-title: Association of large noncoding RNAexpression and its downstream intergenic CpG island methylation with survival in breast cancer.
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-012-2314-z
– volume: 40
  start-page: 703
  year: 2008
  ident: 21
  article-title: Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer.
  publication-title: Nat Genet
  doi: 10.1038/ng.131
– volume: 113
  start-page: 2526
  year: 2009
  ident: 32
  article-title: A myelopoiesis-associated regulatory intergenic noncoding RNA transcript within the human HOXA cluster.
  publication-title: Blood
  doi: 10.1182/blood-2008-06-162164
– volume: 102
  start-page: 8315
  year: 2005
  ident: 31
  article-title: Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer.
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0408974102
– volume: 5
  start-page: 764
  year: 2014
  ident: 3
  article-title: Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer.
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.1769
– volume: 13
  start-page: R85
  year: 2011
  ident: 36
  article-title: Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.
  publication-title: Breast Cancer Res
  doi: 10.1186/bcr2937
– volume: 1
  start-page: 107
  year: 2007
  ident: 41
  article-title: On testing the significance of gene sets.
  publication-title: Ann Appl Stat
  doi: 10.1214/07-AOAS101
– volume: 98
  start-page: 10869
  year: 2001
  ident: 9
  article-title: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.191367098
– volume: 74
  start-page: 1705
  year: 2014
  ident: 33
  article-title: and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells.
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-13-1896
– volume: 23
  start-page: 1494
  year: 2009
  ident: 1
  article-title: Long noncoding RNAs: functional surprises from the RNA world.
  publication-title: Genes Dev
  doi: 10.1101/gad.1800909
– volume: 27
  start-page: 433
  year: 2011
  ident: 17
  article-title: Noncoding RNAs and enhancers: complications of a long-distance relationship
  publication-title: Trends Genet
  doi: 10.1016/j.tig.2011.06.009
– volume: 19
  start-page: R162
  year: 2010
  ident: 12
  article-title: Transcribed dark matter: meaning or myth?
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddq362
– volume: 20
  start-page: 908
  year: 2013
  ident: 6
  article-title: Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer.
  publication-title: Nat Struct Mol Biol
  doi: 10.1038/nsmb.2591
– volume: 20
  start-page: 1109
  year: 2010
  ident: 26
  article-title: Role of H3K27 methylation in the regulation of lncRNA expression.
  publication-title: Cell Res
  doi: 10.1038/cr.2010.114
– volume: 458
  start-page: 223
  year: 2009
  ident: 39
  article-title: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals.
  publication-title: Nature
  doi: 10.1038/nature07672
– start-page: pii
  year: 2014
  ident: 4
  article-title: Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells
  publication-title: Biochem Biophys Res Commun
– volume: 27
  start-page: 1160
  year: 2009
  ident: 10
  article-title: Supervised risk predictor of breast cancer based on intrinsic subtypes.
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2008.18.1370
– volume: 6
  start-page: 289
  year: 2012
  ident: 25
  article-title: The molecular profile of luminal B breast cancer.
  publication-title: Biologics
– volume: 26
  start-page: 1
  year: 2008
  ident: 18
  article-title: Molecular subtypes in breast cancer evaluation and management: divide and conquer.
  publication-title: Cancer Invest
  doi: 10.1080/07357900701784238
– volume: 28
  start-page: 495
  year: 2010
  ident: 19
  article-title: GREAT improves functional interpretation of cis-regulatory regions.
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.1630
– volume: 10
  start-page: 155
  year: 2009
  ident: 13
  article-title: Long non-coding RNAs: insights into functions.
  publication-title: Nat Rev Genet
  doi: 10.1038/nrg2521
– volume: 102
  start-page: 15545
  year: 2005
  ident: 40
  article-title: Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0506580102
– volume: 143
  start-page: 46
  year: 2010
  ident: 22
  article-title: Long noncoding RNAs with enhancer-like function in human cells.
  publication-title: Cell
  doi: 10.1016/j.cell.2010.09.001
– volume: 21
  start-page: 194
  year: 2011
  ident: 16
  article-title: Long non-coding RNAs and enhancers.
  publication-title: Curr Opin Genet Dev
  doi: 10.1016/j.gde.2011.01.020
– volume: 22
  start-page: 1775
  year: 2012
  ident: 24
  article-title: The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression.
  publication-title: Genome Res
  doi: 10.1101/gr.132159.111
– volume: 121
  start-page: 3786
  year: 2011
  ident: 7
  article-title: Heterogeneity in breast cancer.
  publication-title: J Clin Invest
  doi: 10.1172/JCI60534
– volume: 3
  start-page: 167
  year: 2011
  ident: 30
  article-title: ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.
  publication-title: EMBO Mol Med
  doi: 10.1002/emmm.201100122
– volume: 4
  start-page: e1000176
  year: 2008
  ident: 29
  article-title: Differentiating protein-coding and noncoding RNA: challenges and ambiguities.
  publication-title: PLoS Comput Biol
  doi: 10.1371/journal.pcbi.1000176
– volume: 148
  start-page: 1015
  year: 2012
  ident: 20
  article-title: Slug and Sox9 cooperatively determine the mammary stem cell state.
  publication-title: Cell
  doi: 10.1016/j.cell.2012.02.008
– volume: 100
  start-page: 11606
  year: 2003
  ident: 34
  article-title: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1933744100
– start-page: pii
  year: 2014
  ident: 5
  article-title: The long non-coding RNA-derived miR-675 modulates human gastric cancer cell proliferation by targeting tumor suppressor RUNX1
  publication-title: Biochem Biophys Res Commun
– volume: 25
  start-page: 1915
  year: 2011
  ident: 23
  article-title: Integrative annotation of human large intergenic noncoding RNAs reveals global properties and specific subclasses.
  publication-title: Genes Dev
  doi: 10.1101/gad.17446611
– volume: 2
  start-page: e47
  year: 2006
  ident: 28
  article-title: Complex Loci in human and mouse genomes.
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.0020047
– volume: 464
  start-page: 1071
  year: 2010
  ident: 14
  article-title: Long non-coding RNAreprograms chromatin state to promote cancer metastasis.
  publication-title: Nature
  doi: 10.1038/nature08975
– volume: 29
  start-page: 742
  year: 2011
  ident: 35
  article-title: Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.1914
– volume: 5
  start-page: 183
  year: 2008
  ident: 37
  article-title: Whole-genome sequencing and variant discovery in C. elegans
  publication-title: Nat Methods
  doi: 10.1038/nmeth.1179
– volume: 406
  start-page: 747
  year: 2000
  ident: 8
  article-title: Molecular portraits of human breast tumours.
  publication-title: Nature
  doi: 10.1038/35021093
– volume: 21
  start-page: 354
  year: 2011
  ident: 2
  article-title: Long noncoding RNAs and human disease.
  publication-title: Trends Cell Biol
  doi: 10.1016/j.tcb.2011.04.001
– volume: 454
  start-page: 766
  year: 2008
  ident: 27
  article-title: Genome-scale DNA methylation maps of pluripotent and differentiated cells.
  publication-title: Nature
  doi: 10.1038/nature07107
– volume: 17
  start-page: 33
  year: 2012
  ident: 11
  article-title: Non-coding RNAs as regulators of mammary development and breast cancer.
  publication-title: J Mammary Gland Biol Neoplasia
  doi: 10.1007/s10911-012-9245-5
– volume: 11
  start-page: R106
  year: 2010
  ident: 38
  article-title: Differential expression analysis for sequence count data.
  publication-title: Genome Biol
  doi: 10.1186/gb-2010-11-10-r106
– reference: 20436461 - Nat Biotechnol. 2010 May;28(5):495-501
– reference: 21330130 - Curr Opin Genet Dev. 2011 Apr;21(2):194-8
– reference: 11553815 - Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
– reference: 23728290 - Nat Struct Mol Biol. 2013 Jul;20(7):908-13
– reference: 19182780 - Nature. 2009 Mar 12;458(7235):223-7
– reference: 21337521 - EMBO Mol Med. 2011 Mar;3(3):167-80
– reference: 18204455 - Nat Methods. 2008 Feb;5(2):183-8
– reference: 21965334 - J Clin Invest. 2011 Oct;121(10):3786-8
– reference: 24491801 - Cancer Res. 2014 Mar 15;74(6):1705-17
– reference: 20393566 - Nature. 2010 Apr 15;464(7291):1071-6
– reference: 20680032 - Cell Res. 2010 Oct;20(10):1109-16
– reference: 18438407 - Nat Genet. 2008 Jun;40(6):703-6
– reference: 24631686 - Biochem Biophys Res Commun. 2014 Apr 4;446(2):448-53
– reference: 24519926 - Oncotarget. 2014 Feb 15;5(3):764-74
– reference: 22955988 - Genome Res. 2012 Sep;22(9):1775-89
– reference: 22956860 - Biologics. 2012;6:289-97
– reference: 20798109 - Hum Mol Genet. 2010 Oct 15;19(R2):R162-8
– reference: 19571179 - Genes Dev. 2009 Jul 1;23(13):1494-504
– reference: 19144990 - Blood. 2009 Mar 12;113(11):2526-34
– reference: 21831473 - Trends Genet. 2011 Oct;27(10):433-9
– reference: 21804560 - Nat Biotechnol. 2011 Aug;29(8):742-9
– reference: 21550244 - Trends Cell Biol. 2011 Jun;21(6):354-61
– reference: 23124417 - Breast Cancer Res Treat. 2012 Dec;136(3):875-83
– reference: 19188922 - Nat Rev Genet. 2009 Mar;10(3):155-9
– reference: 21890647 - Genes Dev. 2011 Sep 15;25(18):1915-27
– reference: 24388988 - Biochem Biophys Res Commun. 2014 Jun 6;448(3):315-22
– reference: 14500907 - Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11606-11
– reference: 20979621 - Genome Biol. 2010;11(10):R106
– reference: 20887892 - Cell. 2010 Oct 1;143(1):46-58
– reference: 22350981 - J Mammary Gland Biol Neoplasia. 2012 Mar;17(1):33-42
– reference: 19043537 - PLoS Comput Biol. 2008 Nov;4(11):e1000176
– reference: 18181038 - Cancer Invest. 2008 Feb;26(1):1-10
– reference: 21888627 - Breast Cancer Res. 2011;13(5):R85
– reference: 16683030 - PLoS Genet. 2006 Apr;2(4):e47
– reference: 22385965 - Cell. 2012 Mar 2;148(5):1015-28
– reference: 15914550 - Proc Natl Acad Sci U S A. 2005 Jun 7;102(23):8315-20
– reference: 19204204 - J Clin Oncol. 2009 Mar 10;27(8):1160-7
– reference: 18600261 - Nature. 2008 Aug 7;454(7205):766-70
– reference: 10963602 - Nature. 2000 Aug 17;406(6797):747-52
– reference: 16199517 - Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
SSID ssj0000547829
Score 2.4832277
Snippet Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 9864
SubjectTerms Breast Neoplasms - classification
Breast Neoplasms - genetics
Breast Neoplasms - metabolism
Cell Transformation, Neoplastic - genetics
Female
Gene Expression
Humans
MCF-7 Cells
Receptor, ErbB-2 - biosynthesis
Research Paper
RNA, Long Noncoding - analysis
RNA, Long Noncoding - biosynthesis
RNA, Long Noncoding - classification
RNA, Long Noncoding - genetics
RNA, Messenger - genetics
RNA, Messenger - metabolism
Survival Rate
Title Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes
URI https://www.ncbi.nlm.nih.gov/pubmed/25296969
https://www.proquest.com/docview/1624934341
https://pubmed.ncbi.nlm.nih.gov/PMC4259443
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA6uXryI4mt9LBG8eIhum0ebg4iIDwQ9iIt7K2ma6sLSarsL-u-dabu7rooghfbQNISZpPNNZvINIYcmDjSmBjGnOGfCjzkzwikW8iT0UqGtrXi67-7VTU_c9mV_djy6EWD5q2uH9aR6xfD4_e3jDBb8KS74UHH_JEcegypx-tgXUrTIUhUtwkS-BuzXTN8CzKGuwsxCM8DSvIlb_tbJvJ36AT6_51B-MUpXq2SlQZP0vFb_Gllw2Tp5wjVeuJc6NZ2ahnaE5ikd5tkzBYef2RxtFn24Py_pIKNVpT4aY4L6iFqcCAWdnJmk5TjGjdpyg_SuLh8vblhTP4FZofwRs9p5vtEAgWQ3ibmzPOVwNy7wZCJDA2BLuqSr0jRMfcQVUoO_IDX30lA5GfBNsghDctuEekjcJxKTWHjaAL0qEyI2NMpPlVVtcjKRVmQbcnGscTGM0MlA-UYz-UYo3zY5mn7xWhNr_NH2YKKACGY_hjRM5vJxGXkK3EcuwBS3yVatkGlvPoaU4WqTYE5V0wbIrD3_Jhu8VAzb8CPTQvCdf4xxlywDlhKVWevukcVRMXb7gFdGcYe0rvtep5qMn9xV7uw
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comprehensive+analysis+of+long+non-coding+RNAs+in+human+breast+cancer+clinical+subtypes&rft.jtitle=Oncotarget&rft.au=Su%2C+Xiaoping&rft.au=Malouf%2C+Gabriel+G.&rft.au=Chen%2C+Yunxin&rft.au=Zhang%2C+Jianping&rft.date=2014-10-30&rft.issn=1949-2553&rft.eissn=1949-2553&rft.volume=5&rft.issue=20&rft.spage=9864&rft.epage=9876&rft_id=info:doi/10.18632%2Foncotarget.2454&rft.externalDBID=n%2Fa&rft.externalDocID=10_18632_oncotarget_2454
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1949-2553&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1949-2553&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1949-2553&client=summon